BioCentury | Jul 31, 2020
Distillery Therapeutics

Vesicular trafficking protein fusion targets for metastatic osteosarcoma

...migration, and vesicle trafficking protein RAB22A fusions could treat metastatic osteosarcoma bearing the mutations. The RAB22A...
...RAB22A fusions reduced lung metastases and extended survival. TARGET/MARKER/PATHWAY: Rap1 GTPase-GDP dissociation stimulator 1 (RAP1GDS1); RAB22A member RAS oncogene family (RAB22A)...
...Chen, Soochow University, Suzhou, China email: chenjian@cibr.ac.cn Claire Quang Sun Yat-sen University Soochow University Rap1 GTPase-GDP dissociation stimulator 1 (RAP1GDS1) RAB22A member RAS oncogene family (RAB22A)...
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Cancer

...Publication and contact information Cancer Breast cancer RAS oncogene family member RAB22A In vitro and mouse studies suggest inhibiting RAB22A...
...RAB22A transcription. In in vitro invasion or in vivo metastasis assays in mice, microvesicles from RAB22A-depleted...
...from cells expressing normal levels of RAB22A. Next steps could include identifying strategies to target RAB22A-producing...
Items per page:
1 - 2 of 2